| Name | Title | Contact Details |
|---|
AudioNet is a National Provider Network that sub-contracts with various Hearing Aid networks throughout the country to give eligible members the best selection of product and service under one network administrator. We have successfully sub-contracted with over 5,000 Audiologists/ENTs nationally to meet the contractual requirements of our customers, as well as the members needs. Mandating only the most qualified providers to service our members and monitoring the quality of products rendered, AudioNet is able to bring a level of Provider Accountability to the Hearing Aid industry that has never before been seen. Negotiating for State of the Art digital products within a National Provider Network allows the eligible member a tremendous benefit enhancement of upto Two (2) Standard Digital Hearing Aids, covered in full. The Fee Schedules, Product Models and Styles, etc., approved for distribution In-Network are outlined on this website.
Pro-Dex, Inc. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The American Society of Anesthesiologists is an educational, research and scientific association of physicians organized to raise the standards of the medical practice of anesthesiology and to improve patient care.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.